**Supplementary Material**

**Table of Contents**

<table>
<thead>
<tr>
<th>Pages</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 - 4</td>
<td>Supplementary Table 1: key observational studies on anticoagulation timing</td>
</tr>
<tr>
<td>5</td>
<td>Supplementary references</td>
</tr>
</tbody>
</table>
Supplementary Table 1: Key observational studies of outcomes after AF-associated acute stroke according to anticoagulation timing

<table>
<thead>
<tr>
<th>Study</th>
<th>Population and OAC type</th>
<th>Timing groups</th>
<th>Data on stroke severity, size and HT</th>
<th>Follow-up period</th>
<th>Ischaemic outcomes</th>
<th>Bleeding outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOACISP (1)</td>
<td>155 participants 100% DOAC</td>
<td>≤7d: n = 100  &gt;7d: n = 55</td>
<td>NIHSS by timing group: ≤7d: 3 (1-7) &gt;7d: 7 (3-14)</td>
<td>3-6m (mean 140d)</td>
<td>IS annualised rate: ≤7d: 5.1% &gt;7d: 9.3%</td>
<td>sICH annualised rate: ≤7d: 0.0% &gt;7d: 0.0%</td>
</tr>
<tr>
<td>RAF-NOACs (2)</td>
<td>1127 participants 100% DOAC</td>
<td>0-2d: n = 153 3-14d: n = 710 &gt;14d: n = 264</td>
<td>Mean NIHSS: 7.7 (6.2) Infarct size *: 40.9% small, 33.3% medium, 22.1% large Any HT at baseline: 9.1%</td>
<td>90d</td>
<td>IS, TIA, SE, sICH, and major extracranial bleeding: - 0-2d: 12.4% - 3-14d: 2.1% - &gt;14d: 9.1%</td>
<td></td>
</tr>
<tr>
<td>CROMIS-2 (3)</td>
<td>1355 participants 37% DOAC 63% VKA</td>
<td>0-4d: n = 358 &gt; 4d: n = 977</td>
<td>NIHSS by timing group: 0-4d: 2 (1-4) &gt;4d: 6 (3-11)</td>
<td>90d</td>
<td>Ischaemic stroke: 0-4d: 0.8% &gt;4d: 1.6%</td>
<td>sICH: 0-4d: 0.0% &gt;4d: 0.2%</td>
</tr>
<tr>
<td>RELAXED (4)</td>
<td>1305 participants 100% DOAC</td>
<td>&lt;3d: n = 584 3-7d: n = 435 8-14d: n = 198 &gt;14d: n = 88</td>
<td>Median NIHSS: 8 (3-17) Median initiation by NIHSS: &lt;4: 2.8d 4-13: 3.5d &gt;14: 4.6d</td>
<td>90d</td>
<td>Ischaemic stroke: &lt;3d: 1.5% 3-7d: 2.5% 8-14d: 2.0% &gt;14d: 6.8%</td>
<td>sICH: &lt;3d: 0.2% 3-7d: 0.9% 8-14d: 0.0% &gt;14d: 0.0%</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Anticoagulant</td>
<td>≤72h n</td>
<td>&gt;72h n</td>
<td>NIHSS by timing group:</td>
<td>IS/TIA:</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>---------------</td>
<td>--------</td>
<td>--------</td>
<td>------------------------</td>
<td>--------</td>
</tr>
</tbody>
</table>
| SAMURAI-NVAF (5) | 499 participants | 100% DOAC | 223 | 276 | ≤72h: 3 (1-8)  
>72h: 5 (2-13.5)  
Infarct size by timing group:  
≤72h: 36.4% small, 55.3% medium,  
8.3% large  
>72h: 25.3% small, 55.5% medium,  
19.2% large | 90d | ≤72h: 9.4%  
>72h: 10.5% | ≤72h: 0.5%  
>72h: 1.5% |
| IAC (6) | 1289 participants | 67.6% DOAC, 31.0% VKA | 617 | 535 | 137 | NIHSS by timing group:  
0-3d: 5 (1-9)  
4-14d: 10 (4-16)  
>14d: 15 (9-21)  
Infarcts >60cm³ by timing group:  
0-3d: 5.9%  
4-14d: 17.4%  
>14d: 32.8%  
Any (HI/PH) HT at baseline:  
0-3d: 8.6%  
4-14d: 18.7%  
>14d: 48.9% | 90d | IS/TIA/SE:  
0-3d: 10.3%  
4-14d: 9.7%  
>14d: 10.2% | sICH:  
0-3d: 0.3%  
4-14d: 1.7%  
>14d: 2.9% |
<table>
<thead>
<tr>
<th>ALVO</th>
<th>686 participants 100% DOAC Acute LVO or stenosis</th>
<th>NIHSS by timing group:</th>
<th>90d</th>
<th>IS:</th>
<th>sICH:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;48h: n = 263 ≥48h: n = 423</td>
<td>&lt;48h: 12 (7-18)</td>
<td>≥48h: 14 (6-20)</td>
<td>&lt;48h: 3.5%</td>
<td>≥48h: 1.1%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥48h: 0.5%</td>
<td>≥48h: 1.0%</td>
</tr>
</tbody>
</table>

DOAC: direct oral anticoagulant; IS: ischaemic stroke; LVO: large vessel occlusion; OAC: oral anticoagulant; SE: systemic embolism; sICH: symptomatic intracranial haemorrhage; TIA: transient ischaemic attack; VKA: vitamin K antagonist

* small: <1.5cm³; medium: MCA deep or superficial branch, internal borderzone, superficial ACA or PCA branch; large: complete ACA, MCA, or PCA territory, two superficial or one superficial and one deep MCA branches, >1 arterial territory, lesion >1.5cm³ in brainstem or cerebellum; * small: <1.5cm maximum diameter; large: >1/3rd ACA, MCA, or PCA territory, or cerebellar hemisphere; medium: all others.
Supplementary References


